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The 2013-2016 epidemic of Ebola virus disease (EVD) in West Africa has sometimes 
demonstrated stark limitations of our knowledge, but also provided an opportunity to 
enhance our understanding of this dangerous and often mysterious disease. Albeit 
unwelcome, the sheer magnitude of almost 30,000 cases in West Africa provides a much 
larger sample size from which observations can be made, augmented by the 27 cases seen 
in advanced medical settings in Europe and the United States where more detailed clinical 
observation and laboratory analysis were often possible. Perhaps at the top of the list of 
new and sometimes surprising findings are those that relate to sequelae, delayed virus 
clearance, and recrudescent disease in EVD survivors. 
 
 
Prior to reports from the West Africa outbreak, only two controlled studies of EVD survivors 
had been published.1,2 Both highlighted an array of sequelae lasting months to years, 
including extreme fatigue, anorexia, headache, arthralgia, myalgia, abdominal pain, sleep 
disturbance, hearing loss, and visual disturbances. However, neither study incorporated the 
detailed microbiological and physical examination (especially ocular, audiometric, and 
mental health exams) required for a thorough understanding of EVD sequelae and 
associated pathogenesis. Reports emerging in the wake of the massive outbreak in West 
Africa corroborate and expand earlier findings. These include the observation of new ocular 
symptoms in over 60% of EVD survivors, with sight-threatening uveitis in 18.1%, some of 
whom progress to early cataract formation.3,4 Neurological deficits, including seizures, and 
various skin problems, have also been noted.4 Lastly, mental health sequelae are 
unsurprisingly common in survivors and their family members and communities; included 
are sleep and memory disturbances, anxiety disorders, depression, posttraumatic stress 
disorder, and survivors’ guilt.  
 
 
The underlying pathogenesis of EVD sequelae is not well understood, but anecdotal 
observations increasingly suggest that at least some sequelae relate to virus persistence for 
months or even years in selected immunologically protected tissue compartments and 
fluids. These include the testes/semen, chambers of the eye, central nervous 
system/cerebrospinal fluid (CSF), and the fetus, placenta, and amniotic sac/fluid of women 
infected during pregnancy (Figure).4 In many cases, only molecular evidence of viral RNA by 
RT-PCR is available, with no confirmatory cell culture, leaving open the question of whether 
the findings represent inconsequential residual RNA or infectious virus with continued risk 
of transmission.  
 
 
Particularly vexing is the possibility of virus persistence during pregnancy. Maternal 
mortality in pregnant women with EVD is high, and fetal and neonatal mortality nearly 
100%.5 However, a few cases have been noted in West Africa in which women, possibly with 
asymptomatic infection or atypically mild disease, have recovered and remained pregnant, 
only to spontaneously abort a macerated and nonviable fetus in subsequent weeks or 
months.4,6 Although the mothers’ blood remained free of virus at the time of delivery, 
swabs of the fetus, placenta, and amniotic fluid in some cases have tested RT-PCR positive 
for Ebola virus. 
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Two cases of prolonged virus persistence associated with recrudescence have been well-
documented. In the United States, Ebola virus was detected by PCR and cell culture from the 
aqueous humor of a medically evacuated healthcare worker with severe uveitis 14 weeks 
after disease onset and 9 weeks after clearance from the blood, which remained negative 
during the episode of uveitis.7 Importantly, viral RNA was not detected in tear film or 
conjunctival swab specimens, suggesting that the virus remains confined to the intra-ocular 
compartment. In the United Kingdom, Ebola virus was noted by RT-PCR in both the CSF and 
blood in a medically evacuated healthcare worker who developed severe meningitis with 
seizures nine months after resolution of acute disease.8 The RNA copy number was lower in 
the blood than in the CSF, and virus could be isolated in cell culture only from the CSF, 
leading to the conclusion that the viraemia was due to reseeding of the blood from the 
central nervous system. No obvious underlying immunosuppressive condition or trigger for 
virus reactivation could be identified in these cases.  
 
 
Fortunately, recrudescent disease and viraemia after EVD appear to be rare. With the 
exception of sporadic cases of sexual transmission related to persistent virus in the semen, 
no cases of secondary transmission from survivors have been reported. Furthermore, 
accumulating evidence does not suggest prolonged shedding in other body fluids, at least in 
the absence of fever and other acute symptoms.9,10 One theory for the apparent rarity of 
recrudescent cases is that such cases are the consequence of severe initial EVD, which is 
directly related to level of viraemia, with high viraemia seeding the immune-privileged sites. 
Indeed, both patients described above had very high viraemia and severe disease requiring 
intensive care (including, in one case, prolonged mechanical ventilation and haemodialysis). 
Without the intensive medical care usually afforded to medically evacuated patients in 
resource rich countries, such severe disease would usually be fatal in West Africa, leaving 
few survivors at risk of recrudescence. Alternatively, recrudescent disease in West Africa 
may simply be undetected or misattributed to malaria or other common causes of febrile 
disease due to a low index of suspicion and limited diagnostic capacity. Indeed, there are 
anecdotal reports of recrudescent disease and viraemia in West Africa, possibly related to 
underlying HIV infection, although this association has not been validated.  
 
 
Even if infrequent, the possibility of recrudescent disease and virus shedding obligates 
developing appropriate guidelines for the management of EVD survivors that maximize 
health care worker protection while offering highest quality care without precipitation of 
undue fear and stigma. In the absence of evidence of external virus shedding (excluding 
virus in the semen) from asymptomatic EVD survivors, standard precautions are 
recommended for routine clinical examination and care.11 In the UK all EVD survivors should 
be assigned to a designated infectious diseases unit where they will can receive routine 
follow up and guidance.12 Should the patient become unwell, consultation with the 
designated infectious disease unit and the Rare and Imported Fever Service at Public Health 
England should be undertaken immediately to assess risk, arrange laboratory testing for 
EVD, and advise on appropriate infection prevention and control measures, including 
appropriate handling of biological samples.13  
 
4 
 
 
When in doubt, or in emergencies when expert guidance is not yet available, EVD survivors 
presenting with acute febrile or meningo-encephalitic syndromes should be placed in 
isolation and EVD infection prevention and control precautions applied, including the 
wearing of full personal protective equipment.13,14 This applies, but is not limited to, 
attending to deliveries of women who were infected with Ebola virus while pregnant, 
performing emergency surgical procedures or attending to penetrating trauma that involves 
the eye, male genitourinary tract, brain and spinal cord, or female breast, and aliquotting 
specimens or performing centrifugation. Special attention should be given to appropriate 
waste, sharps and linen management, as well as strict adherence to environmental cleaning 
and decontamination protocols of reusable medical equipment. Blood, tissue and organ 
donation from EVD survivors is currently prohibited in the UK and should be deferred until 
further data are available on the precise duration of infectious virus in the various body 
compartments and potential triggers of virus reactivation. Should exposure to Ebola virus be 
suspected, various options for post-exposure prophylaxis exist, but must be considered 
experimental in the absence of systematically collected efficacy or safety data.15 
 
 
The estimated over 10,000 EVD survivors from the West Africa outbreak present a moral 
imperative to provide the required medical care as well as an opportunity to collect the 
evidence necessary to inform future guidelines for effective and safe medical care of this 
vulnerable group.4 The World Health Organization has published interim guidelines for 
clinical care of EVD survivors.16 Acquiring the necessary scientific evidence must start with 
heightened yet non-stigmatizing surveillance and testing to document the duration of virus 
persistence in each body compartment or fluid and the nature and frequency of 
recrudescent disease and secondary transmission. Understanding the relationship between 
viral infectivity and detection of RNA by RT-PCR, a technique now widely available in the 
field during outbreaks, will be key to determining its practical utility in risk estimation. Full 
genome sequencing of Ebola viruses identified during acute infection and recrudescence 
may help shed light on the mechanisms of these events, especially the possibility of escape 
mutants.17 Basic science research will also be needed to identify the implicated cellular 
reservoirs and immune mechanisms of virus persistence. Clinical research is also needed to 
identify the best strategies to both alleviate symptoms and eliminate virus in survivors. 
Various West African studies planned or currently underway promise in time to yield a 
wealth of new information, including the PREVAIL III study detailing sequelae and viral 
persistence in a 5 year controlled cohort of more than 1,500 Liberian EVD survivors.18 
Meanwhile, prudence not panic, is in order in the clinical management of EVD survivors. 
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FIGURE LEGEND 
 
Figure. Virus persistence after the day of disease onset in various body compartments in 
survivors of Ebola virus disease, as detected by reverse-transcription polymerase chain 
reaction (RT-PCR, green) and cell culture (blue). Red bars represent the day of the first 
negative RT-PCR detection in the patient’s blood, when available. Reprinted with permission 
from Vetter et al.4 
 
 
 
